Aceclidine

Summary

Aceclidine (CHEMBL20835) is a phase-3 clinical-stage small molecule (ATC S01EB08); indicated across 2 conditions including glaucoma and presbyopia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: S01EB08 (+1 more)
• Indications: 2 conditions
• Clinical trials: 8
• Chemistry: 169.22 Da · C9H15NO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL20835
Name	Aceclidine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	1979
ATC	S01EB08, S01EB58
Molecular formula	C9H15NO2
Molecular weight	169.22
InChIKey	WRJPSSPFHGNBMG-UHFFFAOYSA-N

SMILES: CC(=O)OC1CN2CCC1CC2

IUPAC name: 1-azabicyclo[2.2.2]octan-3-yl acetate

Also known as: Aceclidina, Aceclidine, Aceclidine hcl, Aceclidine hydrochloride, NSC-657843, NSC-758239, SID26751840, SID507906, ACECLIDINE, (+)-aceclidine, aceclidine

Parent form; salt/anhydrous children: CHEMBL4303558

Patent coverage: 491 distinct patent families (1,620 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Muscarinic acetylcholine receptor, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M3.

Bioactivity

ChEMBL activities: 8 potent at pChembl ≥ 5 of 8 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P08482	6.92	IC50	120	nM	CHEMBL_ACT_139979
P08482	6.29	IC50	510	nM	CHEMBL_ACT_1194755
P08482	6.29	IC50	510	nM	CHEMBL_ACT_937805
P08482	5.62	IC50	2427	nM	CHEMBL_ACT_139980
CHRM1	5.35	EC50	4466	nM	CHEMBL_ACT_139982
CHRM2	5.12	AC50	7510	nM	CHEMBL_ACT_25195863
P08482	5.08	Ki	8260	nM	CHEMBL_ACT_935266
Q9ERZ3	5	EC50	10000	nM	CHEMBL_ACT_172685

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
glaucoma	3	MONDO:0005041	MONDO:0005041
presbyopia	2	MONDO:0001330	MONDO:0001330

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE3	4
PHASE2	3
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05656027	PHASE3	COMPLETED	Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia
NCT05728944	PHASE3	COMPLETED	Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia
NCT05753189	PHASE3	COMPLETED	Phase 3 Safety Study of LNZ100 and LNZ101 for the Treatment of Presbyopia Subjects
NCT06045299	PHASE3	COMPLETED	Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia
NCT03201562	PHASE2	COMPLETED	A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia
NCT05294328	PHASE2	COMPLETED	Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia
NCT05431543	PHASE2	COMPLETED	Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia
NCT05936489	PHASE1	COMPLETED	Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).